Cronos Group Inc. Common Share
2.4900+0.02 (+0.81%)
Oct 28, 4:00:01 PM EDT · NasdaqGM · CRON · USD
Key Stats
Market Cap
954.41MP/E (TTM)
49.80Basic EPS (TTM)
0.05Dividend Yield
0%Recent Filings
8-K
Exec termination for cause
Cronos Group terminated Lloyd Wilson as Vice President, Controller, and Principal Accounting Officer on August 29, 2025, for cause, effective immediately. The move bears no ties to financial results, operations, internal controls, or any disputes over reporting practices. Leadership shakeup hits accounting desk. No successor named yet.
8-K
Q2 revenue surges 21%
Cronos Group reported Q2 2025 net revenue of $33.5 million, up 21% year-over-year, driven by record Israel sales and Cronos GrowCo consolidation, boosting gross margin to 43% from 23%. While Canadian flower constraints lingered, international expansion propelled Adjusted EBITDA to $1.7 million. Leadership appointed Lloyd Wilson as Principal Accounting Officer on August 7, 2025. Strong cash position at $834 million fuels global growth.
10-Q
Q2 FY2025 results
Cronos Group posted net revenue of $33.5M for Q2 FY2025 ended June 30, 2025, up 21% y/y from $27.8M, with gross profit surging 130% y/y to $14.5M and gross margin expanding to 43% from 23% on higher flower sales in Israel (up 36% y/y to $9.4M) and other countries, plus Cronos GrowCo consolidation adding $2.2M. Operating loss narrowed to $5.3M from $15.6M y/y, driven by lower G&A and share-based comp, while diluted EPS held at -$0.10 amid anti-dilution from 385M shares. Cash sits at $794M with $40M in short-term investments; free cash flow not disclosed in the 10-Q. The Q2 Cronos GrowCo acquisition, closed July 2024 for no cash (preexisting $53.5M equity), recognized $65.3M goodwill and $8.0M know-how intangibles amortized over 10 years, boosting supply for international growth. Yet regulatory pressures in Israel, like the ongoing anti-dumping probe, cloud export momentum.
8-K
Annual meeting results
Cronos Group Inc. held its 2025 Annual Meeting of Shareholders on June 20, 2025, where all seven director nominees—Michael Gorenstein, Jason Adler, Murray Garnick, Kamran Khan, Dominik Meier, Elizabeth Seegar, and James Rudyk—were elected with strong majorities, receiving between 206 million and 216 million 'for' votes amid 17 million withheld. Shareholders approved the advisory resolution on executive compensation by a 210 million to 12.6 million margin, while ratifying Davidson & Company LLP as auditors for fiscal 2025 with 273 million supportive votes. This clean sweep signals robust investor confidence in the board's direction. No major dissent emerged.
10-Q
Q1 FY2025 results
Cronos Group swung to a $6.1M net profit in Q1 FY2025 ended March 31, 2025, up from a $2.2M loss y/y, fueled by 28% revenue growth to $32.3M on stronger flower sales in Israel (up 44% to $9.2M) and extracts in Canada, while gross margin leaped to 43% from 18% thanks to production efficiencies and higher volumes. Operating loss narrowed to $4.1M from $15.9M y/y, with expenses down 13% amid lower marketing and no prior impairments; non-GAAP Adjusted EBITDA turned positive at $2.3M from a $10.7M loss (defined and reconciled in the 10-Q). Cash dipped to $798M from $859M q/q after $15.3M capex, but free cash flow stayed negative at -$17.4M (derived); the Cronos GrowCo consolidation added $2.9M revenue and $65.3M goodwill from its Q3 2024 close with no cash outlay. EPS of $0.02 reconciles to 383M diluted shares with no anti-dilution flagged. Yet regulatory threats loom in Israel over potential anti-dumping duties.
IPO
Website
Employees
Sector
Industry
ACB
Aurora Cannabis Inc.
5.01-0.08
CGC
Canopy Growth Corporation
1.29-0.03
CPMD
Cannapharmarx Inc.
0.01+0.00
CRLBF
Cresco Labs Inc.
1.20-0.04
CURLF
Curaleaf Hldgs Inc.
2.82-0.05
GHBWF
-
0.53-0.03
GTBIF
Green Thumb Industries Inc.
7.13-0.28
IMCC
IM Cannabis Corp.
1.41-0.02
MAJI
Marijuana Inc.
0.11+0.01
MRMD
MariMed Inc.
0.13-0.01